Related Experiment Video
Updated: May 5, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Current practices and challenges of adjuvant chemotherapy in patients with colorectal cancer
Christine Brezden-Masley1, Chanele Polenz
1St Michael's Hospital, 30 Bond Street, Room 2081, Toronto, Ontario M5B 1W8, Canada.
Abstract:
Colorectal cancer is one of the most commonly diagnosed cancers in men and women in the developed world. Although surgery is the foundation of curative treatment, adjuvant chemotherapy also improves overall and disease-free survival in high-risk stage II and all stage III patients. Research strongly suggests that the timing from surgery to adjuvant chemotherapy is critical, because delays to the start of treatment significantly affect patient outcomes. Both clinical and systemic barriers, such as postoperative complications and institutional wait times, challenge the timely administration of adjuvant chemotherapy. Further research investigating solutions to overcome these barriers is needed.
More Related Videos
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Treatment Resistant Cancers
Endoscopic Procedures II: Colonoscopy
Drugs for Treatment of Ulcerative Colitis in IBD
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase